AJNR Senior EditorLucien M. Levy
Over the past several years, there has been significant progress in the evaluation of dementias and related conditions. The number of studies and results involving dementias has dramatically increased, in part due to the development and clinical application of advanced imaging techniques, implementation of new laboratory studies, … more »
Sophia Mueller
Tracing the functional and structural connectivity within the brain may provide means to see whether psychiatric illness is fundamentally routed in “connectopathies”—connectional abnormalities that lead to brain dysfunction. So far, only a few studies have combined functional and structural network explorations to ask this very basic question of how anatomic variability affects functional differences. … more »
Rahul Desikan
With regards to our article “Apolipoprotein E (ApoE) ε4 Does Not Modulate Amyloid-β–Associated Neurodegeneration in Preclinical Alzheimer Disease,” we researched this topic because there is a need to better elucidate the pathobiologic changes underlying the earliest stage of Alzheimer disease (AD). Specifically, we wanted to better understand how ApoE ε4, tau, and amyloid … more »
Jeffrey Petrella
As the global population ages, the incidence of Alzheimer disease (AD), now more than 30 million worldwide, is predicted to triple by the year 2050, creating an urgent need for developing therapeutics designed to slow or halt disease progression. The search for a cure continues, and our extensive, yet incomplete, understanding of its … more »
Alison D. Murray
I have been working in brain aging and dementia research for several years and have been excited to see the role of neuroimaging in patients with dementia progress from exclusion of treatable mass lesions, such as tumors or subdurals (which occur in a tiny proportion of those we image), to diagnosis … more »
Kejal Kantarci
Early diagnosis of dementia-related pathology through imaging is the focus of my research program. Decreased glucose metabolism in the temporal and parietal lobes on [18F]fluorodeoxyglucose (FDG) PET is recognized as an early imaging marker for the Alzheimer disease (AD) pathology.
Neuroimaging markers of AD pathology would allow new therapies to be developed more quickly … more »
Joseph A. Helpern
Establishing neuroimaging biomarkers for the early detection of Alzheimer disease (AD) is crucial for the development of disease-modifying therapies. Indeed, investigation of potential neuroimaging biomarkers is one of the key strategies under the first goal of the 2012 National Alzheimer’s Project Act, as well as for President Obama’s BRAIN initiative. Our … more »
“Neuroimaging of Dementias” is the latest Special Collection from the American Journal of Neuroradiology. Collection Editor Lucien M. Levy, also a Senior Editor for AJNR, collected almost 60 articles, arranging them into 8 sections outlining clinical presentations, genetics, and imaging patterns associated with a range of conditions, as well as the diagnostic and evaluative capabilities of various … more »